{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:01Z","timestamp":1777859581848,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>This report explores the potential role of glucagon-like peptide 1 (GLP-1) receptor agonists in minimizing the metabolic side effects of psychotropic medications in patients with underlying type 2 diabetes (T2D) in inpatient psychiatric settings. The introduction of novel antidiabetic medications such as GLP-1 receptor agonists has broadened the options for managing metabolic disorders, particularly T2D. These medications not only offer effective glycemic control but also provide cardiovascular and renal benefits and help with weight management. Given the tendency of psychotropic medications to cause weight gain and metabolic complications, this report presents 2 cases where weekly doses of semaglutide improved blood glucose levels and prevented weight gain in patients receiving chronic psychotropic medications. Integrating GLP-1 receptor agonists into inpatient psychiatric care can help mitigate the metabolic adverse effects of psychotropic medications. However, considerations such as cost, accessibility, and institutional formulary restrictions are essential to ensure comprehensive patient care.<\/jats:p>","DOI":"10.1177\/08971900241294122","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T20:14:17Z","timestamp":1729628057000},"page":"351-356","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-9018","authenticated-orcid":false,"given":"Krysta","family":"Shannon","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Manager, NewYork-Presbyterian Hospital, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Shyh","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Manager, NewYork-Presbyterian Hospital, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2023.03.006"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/ejihpe13080110"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v8.i8.390"},{"issue":"1","key":"e_1_3_6_6_2","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1-93.","journal-title":"CNS Drugs"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0279-3"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05609-x"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003864"},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","unstructured":"Trujillo JM Nuffer W Ellis SL. GLP-1 receptor agonists: A review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19-28.","DOI":"10.1177\/2042018814559725"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1479164112441526"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27134315"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059595"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042018821997320"},{"key":"e_1_3_6_16_2","volume-title":"Byetta (exenatide) injection package insert","year":"2022","unstructured":"Byetta (exenatide) injection package insert. Wilmington, DE: AstraZeneca pharmaceuticals, 2022."},{"key":"e_1_3_6_17_2","volume-title":"Bydureon BCise (exenatide extended-release) injectable suspension package insert","year":"2022","unstructured":"Bydureon BCise (exenatide extended-release) injectable suspension package insert. Wilmington, DE: AstraZeneca Pharmaceuticals; Revised; 2022."},{"key":"e_1_3_6_18_2","volume-title":"Victoza (liraglutide) injection package insert","year":"2023","unstructured":"Victoza (liraglutide) injection package insert. Bagsvaerd, Denmark: Novo Nordisk; 2023."},{"key":"e_1_3_6_19_2","volume-title":"Trulicity (dulaglutide) injection package insert","year":"2023","unstructured":"Trulicity (dulaglutide) injection package insert. Indianapolis: Eli Lilly and Company; 2023."},{"key":"e_1_3_6_20_2","volume-title":"Ozempic (semaglutide) injection package insert","year":"2023","unstructured":"Ozempic (semaglutide) injection package insert. Bagsvaerd, Denmark: Novo Nordisk; 2023."},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12795"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13167"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14334"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-022-00590-1"},{"key":"e_1_3_6_26_2","first-page":"13","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series","volume":"1","author":"Prasad F","year":"2023","unstructured":"Prasad F, De R, Korann V, et al. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. Ther Adv Psychopharmacol. 2023;1:13.","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241294122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900241294122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241294122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:43Z","timestamp":1777509223000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900241294122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/08971900241294122"],"URL":"https:\/\/doi.org\/10.1177\/08971900241294122","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}